Larimar Therapeutics
LRMR
45 hedge funds and large institutions have $61.8M invested in Larimar Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
3.9% more ownership
Funds ownership: 82.26% → 86.15% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 49 → 45 (-4)
61% less capital invested
Capital invested by funds: $157M → $61.8M (-$95.4M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$4.11M |
| 2 |
Morgan Stanley
New York
|
+$3.39M |
| 3 |
Janus Henderson Group
London,
|
+$2.03M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.24M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$393K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.31M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.13M |
| 3 |
FAM
Fred Alger Management
New York
|
-$1.9M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$818K |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$345K |
LRMR Hedge Fund Activity: Q1 2022 in Review
45 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2022, worth a combined $61.8M — down 61% from $157M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LRMR and 2 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was Mangrove Partners, adding an estimated $4.11M. The largest seller was Vivo Capital, exiting entirely with an estimated $4.31M sold.
- 45 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2022, down from 49 in Q4 2021.
- Funds reported $61.8M of Larimar Therapeutics stock for Q1 2022, down 61% quarter-over-quarter.
- 2 funds opened new Larimar Therapeutics positions in Q1 2022 and 6 closed out, a net change of -4 holders.
- The largest Larimar Therapeutics buyer in Q1 2022 was Mangrove Partners, an estimated $4.11M added.
- The largest Larimar Therapeutics seller in Q1 2022 was Vivo Capital, an estimated $4.31M sold.
Based on aggregated 13F filings for Q1 2022.